Patients receiving SCT for the treatment of NDMM between 2000–2015, and with cytogenetic data available, were reported to the EBMT registry (N = 623).Data were obtained from the European Society for Blood and Marrow Transplantation (EBMT) registry, and the results were published in Bone Marrow Transplant-below is a summary. 1 evaluated patients with high-risk NDMM with del(17p) and/or t(4 14) undergoing frontline treatment with single autologous (auto), tandem autologous (auto-auto), or tandem autologous/reduced-intensity allogeneic (auto-allo) stem cell transplantation (SCT). In an endeavor to provide answers, Nico Gagelmann et al. However, the benefit of a tandem transplant remains ill-defined and, until now, no studies have reported alternative transplant approaches in distinct cytogenetic groups in the real-world setting. Among efforts to improve patient outlook, tandem transplantation has been employed in certain settings. Despite significant advances in treatment options for patients with MM in recent decades, certain cytogenic aberrations are still associated with inferior outcomes in MM.Ĭurrently employed standard-of-care regimens for patients with newly diagnosed MM (NDMM) have improved survival outcomes, but patients harboring del(17p) and/or t(4 14) genetic alterations have been identified as particularly high risk, and benefit least from emerging treatments.

As part of this month’s editorial theme, the Multiple Myeloma Hub is focusing on the clinical outlook of high-risk multiple myeloma (MM), and how patient prognosis can be improved in this setting.

Myeloma stem cell transplant